Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT03662789

Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients (IronIC)

Sponsor: Oslo University Hospital

Interventions Iron Isomaltoside 1000 Placebo: NaCl 0,9%

Updated 6 times since 2018 Last updated: Apr 30, 2021 Started: Apr 25, 2018 Primary completion: Feb 27, 2020 Completion: Feb 27, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03662789, this PHASE2/PHASE3 trial focuses on Heart Transplant Recipients and remains completed. Sponsored by Oslo University Hospital, it has been updated 6 times since 2018, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jun 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Jun 2021 [monthly]

Completed PHASE2_PHASE3
Apr 2020 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed

▶ Show 1 earlier version

Oct 2018 — Apr 2020 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oslo University Hospital
Pharmacosmos A/S

Data source: Oslo University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway